A5089741202- Advanced Breast Cancer Therapies
- Inflammatory mediators and NSAID effects
- Cancer Immunotherapy and Biomarkers
- Estrogen and related hormone effects
- Innovations in Medical Education
- Advances in Oncology and Radiotherapy
- PARP inhibition in cancer therapy
- HER2/EGFR in Cancer Research
- Clinical Reasoning and Diagnostic Skills
- Cancer-related cognitive impairment studies
- Breast Cancer Treatment Studies
- Lymphoma Diagnosis and Treatment
- Endometriosis Research and Treatment
- BRCA gene mutations in cancer
- Chronic Lymphocytic Leukemia Research
Instituto Alexander Fleming
2024
e12603 Background: In early triple-negative breast cancer (TNBC) current treatment involves neoadjuvant chemo-immunotherapy (NAC). Patients with residual disease after NAC are at the highest risk of recurrence. Previous studies have shown that tumor regression patterns in luminal primarily exhibit concentric shrinkage, which is associated pathological complete response (pCR). However, scarce TNBC evaluated correlation between imaging shrinkage and response. Therefore, further investigations...
Genomic analysis through various platforms is an essential tool for determining prognosis and treatment in a significant subgroup of early-stage breast cancer patients with hormone receptor-positive human epidermal growth factor receptor 2 (HER2)negative status.Additionally, combined clinical pathological characteristics can accurately predict the recurrence score (RS), as demonstrated by University Tennessee risk nomogram.In this study, we aimed to identify classical clinical-pathological...
Abstract Introduction The recently published NATALEE trial has reported an increase of invasive disease free survival with the addition ribociclib to hormone therapy during 3 years. Given fact that aromatase inhibitors are required as endocrine backbone, premenopausal patients require ovarian function suppression (OFS) CDKi treatment In era in adjuvant setting, we hypothesize recommendation GnRh analogs administration will for patients, given inclusion criteria this pivotal trial. For...
Introducción: El tratamiento estándar para pacientes con cáncer de mama RH+/HER2- avanzado involucra el uso un inhibidor quinasas dependientes ciclinas 4/6 (iCDK4/6), junto terapia hormonal. Se ha demostrado la eficacia ribociclib en sobrevida libre progresión y global. Objetivos: En este estudio se plantea importancia evaluar toxicidad tiempo, es decir, tiempo dedicado a atención médica, entorno del mundo real RH+/HE2- enfermedad avanzada que encuentran recibiendo ribociclib....
Introducción: La formación de oncólogos en Argentina enfrenta diversos desafíos, lo que afecta tanto el desarrollo profesional los médicos como la calidad atención oncológica país. Este estudio explora las percepciones, expectativas y experiencias jóvenes Argentina, con objetivo identificar barreras limitan su proponer soluciones. Métodos: Se utilizó un enfoque mixto (cualitativo cuantitativo) mediante encuestas semi-estructuradas a 57 residentes especialistas oncología menos cinco años...
Next-generation sequencing (NGS) has proven to be a key implementation understanding biological pathways involved in cancer. In daily practice, the identification of somatic and germline mutations allowed physicians gather relevant information make therapeutic decisions benefit patients. Importantly, provide targeted opportunities for treatment reveal resistance mechanisms understand patients' tumour evolution. Scanty data clinical trials real-world setting is available regarding utility...